PAEAN Biotechnology, Inc.
- Country
- 🇰🇷South Korea
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.paeanbio.com
Clinical Trials
2
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis
- Conditions
- PolymyositisDermatomyositis
- Interventions
- Biological: placebo
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Paean Biotechnology Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT07122648
- Locations
- 🇰🇷
Chung-Ang University Gwang Myeong Hospital, Gwangmyeong, Gyeonggi-do, Korea, Republic of
🇰🇷Kyung Hee University Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul National University, Seoul, Korea, Republic of
Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis
- Conditions
- PolymyositisDermatomyositis
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Paean Biotechnology Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT04976140
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Soonchunhyang University Seoul Hospital, Seoul, Korea, Republic of
🇰🇷Hanyang University Seoul Hospital, Seoul, Korea, Republic of
News
RESTEM Receives FDA Orphan Drug Designation for Stem Cell Therapy in Polymyositis Treatment
RESTEM, a clinical-stage biotech company, received FDA Orphan Drug Designation in December 2024 for its umbilical cord outer lining stem cell program targeting polymyositis and dermatomyositis.